Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission
Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
- You are here:
- Home »
- Blog »
- Multiple Myeloma »
- Cardiovascular Aging in Myeloma
Cardiovascular Aging in Myeloma
Cardiovascular aging in myeloma is a different long-term side effect than both cardiotoxicity and chemotherapy-induced cardiomyopathy. Similar issues, but MM survivors must treat each issue a bit differently.
I am not an oncologist or a cardiologist. I am a long-term MM survivor who was diagnosed with chemotherapy-induced cardiomyopathy in 2015. I blog about MM on PeopleBeatingCancer.org in an effort to teach MM patients and survivors about the good, the bad and the ugly about MM.
I have been researching and writing about the heart damage caused by many of the regimens used to treat MM. The list of cardiotoxic regimens has increased as new novel MM therapies have been approved by the FDA.
The research linked below takes the issue of cardiotoxicity a step further by explaining what can happen to MM survivors over time. Various types of chemotherapy age the MM patient. The research below talks about chemo aging the MM patient’s heart and the problems that can stem from that aging of the heart.
Cardiovascular toxicities from cancer treatment
When I was diagnosed with chemotherapy-induced cardiomyopathy, I was prescribed metoprolol. I had a reaction to this common heart medication and decided to research and take evidence-based, non-conventional heart-healthy nutrition and nutritional supplements. The list below is what I take daily for this purpose.
Consider:
- CoQ10
- DHEA
- Omega-3 fatty acids
- Curcumin
- Vitamin D3
- Cocoa
- Carnitine
- D-Ribose
as well as a heart-healthy diet, regular, moderate exercise and plenty of sleep.
Conventional heart meds like metoprolol may be able to solve the problem of cardiovascular aging in myeloma, but I don’t know. In my experience, all conventional medicines have side effects. Many of these side effects can be serious.
My point in writing this post is to explain the basic challenge, and then what I do. My evidence-based non-conventional heart care has stabilized my heart health since my diagnosis in 2015. Further, I am not aware of any side effects from my heart-healthy lifestyle.
I continue to manage my heart health and monitor it with annual echocardiograms.
Have you been diagnosed with MM? What stage? What therapies have you undergone so far? Scroll down the page, post a question or comment, and I will reply to you ASAP.
Hang in there,
David Emerson
- MM Survivor
- MM Cancer Coach
- Director PeopleBeatingCancer
Cancer Therapy-Related Cardiovascular Aging: Mechanisms, Monitoring, and Intervention Strategies
Significant improvements in cancer survival rates have been achieved through advancements in treatment and early diagnosis. However, non-cancer-related mortality among cancer survivors continues to rise each year.
Cardiovascular diseases (CVDs) related to cancer therapy now rank as the second leading cause of death in survivors, sometimes surpassing the cancer itself. Among these, cardiovascular aging represents one of the most severe side effects, often leading to detrimental structural changes such as cardiac atrophy or fibrosis, which ultimately impair cardiac function and reduce survival.
Preventing or treating cardiovascular aging has emerged as a promising strategy to mitigate Cancer Therapy-Related Cardiovascular Toxicity (CTR-CVT). This review offers a comprehensive analysis of the characteristics and mechanisms underlying cancer therapy-induced accelerated cardiovascular cellular senescence, outlines current monitoring and intervention strategies, and explores future research opportunities and challenges.
Enhancing the understanding of Cancer Therapy-Related Cardiovascular Cellular Senescence and Cancer Therapy-Related Cardiovascular Aging (CTR-CVA) is crucial for optimizing cancer treatment, advancing medical research, and improving clinical practice, all of which are vital for preserving cardiac health and improving the quality of life of patients with cancers.
Cardiovascular adverse events in modern myeloma therapy – Incidence and risks
Abstract
Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related to the disease (cardiac AL-amyloidosis, hyperviscosity, high-output failure, arteriovenous shunting, anemia, renal dysfunction) and/or related to anti-myeloma treatment:
- anthracyclines,
- corticosteroids,
- alkylating agents,
- immunomodulatory drugs,
- proteasome inhibitors
Good knowledge of cardiovascular events, effective dose reductions, prevention and management of early and late cardiovascular side effects of chemotherapeutic agents are essential in current clinical practice.
Myeloma experts are obliged to carefully balance the efficacy and toxicity of drugs for each individual patient. This review summarizes current data and novel insights into cardiovascular adverse events of today’s anti-myeloma treatment, focusing on carfilzomib, as a starting point for developing consensus recommendations on preventing and managing cardiovascular side effects in patients with multiple myeloma.
Cardiovascular aging in myeloma Cardiovascular aging in myeloma Cardiovascular aging in myeloma